Gang Li Sheng Gong Ning Wang Xiaojun Yao
10.3389/fimmu.2022.989966
Front Immunol
2022 Aug 26;13:989966.
immune-related adverse events (ir-aes) neoadjuvant therapy non-small cell lung cancer pulmonary tuberculosis toxic epidermal necrolysis
CC BY
https://pubmed.ncbi.nlm.nih.gov/36090976/
Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / pathology Lung Neoplasms / complications Lung Neoplasms / drug therapy Lung Neoplasms / pathology Skin Diseases / chemically induced Stevens-Johnson Syndrome / diagnosis Stevens-Johnson Syndrome / etiology Tuberculosis, Pulmonary / complications Tuberculosis, Pulmonary / diagnosis Tuberculosis, Pulmonary / drug therapy
Carcinoma, Non-Small-Cell Lung / complications Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / pathology Lung Neoplasms / complications Lung Neoplasms / drug therapy Lung Neoplasms / pathology Skin Diseases / chemically induced Stevens-Johnson Syndrome / diagnosis Stevens-Johnson Syndrome / etiology Tuberculosis, Pulmonary / complications Tuberculosis, Pulmonary / diagnosis Tuberculosis, Pulmonary / drug therapy Case Reports Antibodies, Monoclonal, Humanized Humans Antibodies, Monoclonal, Humanized sintilimab
PMC9459224
36090976
Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
2022